Study title:
A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
Long title:
A phase I/II safety, dose finding and feasibility trial of MB-CART2019.1 in patients with relapsed or resistant B-NHL
Date receipt dossier:
2 déc 2019
EU record number:
MB-CART2019.1
EudraCT number:
2018-001253-27
Pharmaceutical study code:
MB-CART2019.1
Company / Sponsor:
Miltenyi Biotech GmbH
Phase:
I/II a
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
relapsed and resistant B-NHL
Therapeutic approach:
Immunotherapy
Genetic modification:
CD19 and CD20 chimeric antigen receptor
Method of transfer of nucleic acid of interest:
lentiviral vectors
Administered biological material:
Autologous T-cells transduced with lentiviral vectors expressing CD19/CD20 CAR
Route of administration:
Intravenous
Locations in Belgium:
UZ Gent, Cliniques universitaires Saint-Luc
Type of procedure:
Contained use only
Current status:
Authorized